AstraZeneca shares up 4.5% after earnings beat and guidance is held
Second quarter results ahead of expectationsFull year outlook and guidance maintainedBuying Pfizer rare diseases portfolio for up to $1 billionAstraZeneca (AZN) delivered better-than-expected second-quarter growth and reiterated...
28 July 2023